Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23264169 | 0.81 | USP1 (0.33) | USP1ALDH1A1 | |
| SCHEMBL23264140 | 0.80 | USP1 (0.30) | USP1 | |
| SCHEMBL25463483 | 0.80 | ALDH1A1 (0.32) | USP1ALDH1A1 | |
| SCHEMBL25464139 | 0.80 | USP1 (0.30) | USP1 | |
| SCHEMBL19705565 | 0.73 | HTR2C (0.33) | HTR2CHTR2AADRB2ADRA2AAXL | |
| SCHEMBL22143277 | 0.71 | USP1 (0.46) | USP1ALDH1A1 | |
| SCHEMBL23264263 | 0.71 | USP1 (0.42) | USP1 | |
| SCHEMBL25728946 | 0.71 | — | — | |
| SCHEMBL25718292 | 0.69 | — | — | |
| SCHEMBL5273467 | 0.68 | ADRB1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083285-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |